Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $25.4615.

A number of analysts have commented on the company. Oppenheimer set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, July 28th. Finally, CLSA set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th.

Kura Oncology Trading Down 3.2%

Shares of Kura Oncology stock opened at $9.01 on Tuesday. Kura Oncology has a 12-month low of $5.45 and a 12-month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The stock has a market cap of $799.82 million, a PE ratio of -2.69 and a beta of 0.35. The company has a 50-day moving average of $10.19 and a two-hundred day moving average of $9.27.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, research analysts anticipate that Kura Oncology will post -3.45 EPS for the current fiscal year.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kura Oncology by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after buying an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in shares of Kura Oncology in the first quarter worth $143,000. Legal & General Group Plc lifted its position in shares of Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after acquiring an additional 18,930 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Kura Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after acquiring an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Kura Oncology by 244.5% during the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after acquiring an additional 165,189 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.